Characterization and translational development of IOA-289, a novel autotaxin inhibitor for the treatment of solid tumors

Background: Autotaxin-lysophosphatidic acid (ATX-LPA) signaling has a predominant role in immunological and fibrotic processes, including cancer. Several ATX inhibitors and LPA receptor antagonists have been clinically evaluated, but none in patients with solid tumors. Many cancers are burdened with...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	M.A. Deken, K. Niewola-Staszkowska, O. Peyruchaud, N. Mikulčić, M. Antolić, P. Shah, A. Cheasty, A. Tagliavini, A. Nizzardo, M. Pergher, L. Ziviani, S. Milleri, C. Pickering, M. Lahn, L. van der Veen, G. Di Conza, Z. Johnson
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Elsevier 2023-06-01
Saila:	Immuno-Oncology and Technology
Gaiak:	autotaxin (ATX) lysophosphatidic acid (LPA) inhibitor immuno-oncology stroma
Sarrera elektronikoa:	http://www.sciencedirect.com/science/article/pii/S2590018823000126
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!